A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a new dosage form and dose of orlistat is equivalent to the currently marketed form.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Orlistat

Criteria

Inclusion Criteria:

• age: 18-60 years

• Body Mass Index: 25-33

Exclusion Criteria:

• gastrointestinal disease

• organ transplant

• HIV, hepatitis B or C

• food allergies

• alcohol or other substance abuse

• smoking